New York City, NY -- (SBWIRE) -- 10/18/2013 -- StockMarketIntel.com issues a special report on the following stocks: F5 Networks, Inc. (NASDAQ:FFIV), Fortinet Inc (NASDAQ:FTNT), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Towers Watson & Co (NYSE:TW)
F5 Networks, Inc. (NASDAQ:FFIV) declined -2.93%, trading on 2.22 million shares, to end the trade at $85.92. If we look at its trading history of the past 52 weeks, the share price suffered a low of $67.53 and was moved to the maximum level of $107.99. The stock changed hands in a range of $85.87 to $88.06, bringing its market capitalization to about $6.73 billion. F5 Networks, Inc. is a provider of Application Delivery Networking (ADN) technology that secures and optimizes the delivery of network-based applications and the security, performance and availability of servers, and other network resources. The Company's principal products are application delivery controllers (ADCs) that include the Company's BIG-IP family of appliances and its line of scalable VIPRION systems.
Will FFIV Get Buyers Even After The Recent Rally? Find Out Here
Fortinet Inc (NASDAQ:FTNT) declined -3.24%, to complete the trading session at $19.69, with a total volume of 2.14million shares. The stock, on average, trades on a volume of 1.96 million shares. In the past 52 weeks, the share price has not declined below $16.47 and above $25.35. It floated in a range of $19.64 to $20.24 during the last trading session, with a beta value of 1.82. Its market capitalization now moved to about $3.20 billion. Fortinet, Inc. (Fortinet) provides network security solutions. Through the Company’s products and subscription services, Fortinet provides integrated and protection against security threats for enterprises, service providers and governmental entities worldwide. Its flagship Unified Threat Management (UTM) solution consists of its FortiGate physical and virtual appliance products that provide a range of security and networking functions, including firewall, virtual private networking (VPN), application control, antivirus, intrusion prevention, Web filtering, vulnerability management, antispam, wireless controller, and wide area network (WAN) acceleration. On December 7, 2012, the Company completed the acquisition of XDN, Inc. (XDN), a privately held company that provides cloud-based content delivery solutions.
Will FTNT Bounce Back After yesterday’s Sharp Sell off? Find Out Here
Celldex Therapeutics, Inc. (NASDAQ:CLDX) recorded a fall of -2.81% and was in a range of $26.62-$27.90 before closing at $27.00. The share price hit its 52-week low of $5.02 and $38.84 was the best price. The stock completed the day with a total volume of 2.03 million shares, versus an average volume of 3.36 million shares. Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company's drug candidates include CDX-110, CDX-011 and CDX-1127. CDX-110, is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII).
Is it the Right to Grab CLDX after the Recent Slump? Get Free Trend Analysis Here
Towers Watson & Co (NYSE:TW) declined -4.42% yesterday, bringing its market capitalization around $8.53 billion. The total number of shares that changed hands during the session was 2.00 million shares, as compared to average trading volume of 802,515 shares. The share price, after opening at $117.25, made a high of $117.56 and hovered above $109.92 to end the day at $112.07. Towers Watson & Co. (Towers Watson) is a global professional services company. The Company offers solutions in the areas of benefits, talent management, rewards, and risks and capital management. The Company offers its clients comprehensive services across four business segments: Benefits, Risk and Financial Services, Talent and Rewards, and exchanges Solutions.
Will TW Reach the Bottom after Yesterday’s Correction? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)